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Abstract
The limitations of steroidal and non steroidal anti-inflammatory drugs have prompted investigation into other
biologically based therapeutics, and identification of immune selective anti-inflammatory agents of salivary origin.
The traditional view of salivary glands as accessory digestive structures is changing as their importance as sources
of systemically active immunoregulatory and anti-inflammatory factors is recognized. Salivary gland involvement in
maintenance of whole body homeostasis is regulated by the nervous system and thus constitutes a “neuroendo-
crine axis”. The potent anti-inflammatory activities, both in vivo and in vitro, of the tripeptide Phe-Glu-Gly (FEG) are
reviewed. FEG is a carboxyl terminal peptide of the prohormone SMR1 identified in the rat submandibular salivary
gland, The D-isomeric form (feG) mimics the activity of its L-isomer FEG. Macropharmacologically, feG attenuates
the cardiovascular and inflammatory effects of endotoxemia and anaphylaxis, by inhibition of hypotension,
leukocyte migration, vascular leak, and disruption of pulmonary function and intestinal motility. Mechanistically, feG
affects activated inflammatory cells, especially neutrophils, by regulating integrins and inhibiting intracellular
production of reactive oxygen species. Pharmacodynamically, feG is active at low doses (100 μg/kg) and has a long
(9-12 hour) biological half life. As a therapeutic agent, feG shows promise in diseases characterized by over exuber-
ant inflammatory responses such as systemic inflammatory response syndrome and other acute inflammatory
diseases. Arthritis, sepsis, acute pancreatitis, asthma, acute respiratory inflammation, inflammatory bowel disease,
and equine laminitis are potential targets for this promising therapeutic peptide. The term “Immune Selective
Anti-Inflammatory Derivatives” (ImSAIDs) is proposed for salivary-derived peptides to distinguish this class of agents
from corticosteroids and nonsteroidal anti-inflammatory drugs.
Introduction
Saliva, best known for its digestive and protective proper-
ties in the maintenance of the health and integrity of the
oral and gastric mucosa [1], is becoming increasingly
recognized for its important role in regulating whole
body homeostasis [2]. Although over the past half cen-
tury many bioactive proteins and peptides have been
identified in saliva [3,4], salivary glands are still viewed
primarily as accessory digestive structures that provide
lubrication and digestive enzymes. However, it is now
becoming clear that salivary endocrine factors play an
important role in the modulation of systemic immune
and inflammatory reactions. Classically, the salivary
glands are generally considered as exocrine glands that
dispense their protein and fluid externally into a lumen
or a duct. However, investigations dating from 60 years
ago suggested an unorthodox view that salivary and other
exocrine glands, such as the pancreas, are capable of
endocrine secretion, dispensing their secretions intern-
ally, i.e. directly into the blood stream. It has been sug-
gested that these glands be called “duacrine” glands [5].
Salivary glands produce various immunoregulatory
[6,7] and anti-inflammatory [8] agents. The importance
of the salivary gland in maintaining homeostasis has
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been clarified in recent decades by demonstration of
neuroendocrine interactions between the nervous, endo-
crine, and immune systems [9]. The salivary glands, as
well as the thymus and cervical lymph nodes, are inner-
vated by noradrenergic fibers from the sympathetic
trunk [10,11], which were shown to modulate lympho-
cyte function within lymph nodes and thymus [12,13].
This paper reviews the published pharmacologic and
immunopharmacologic evidence that salivary gland
derived peptides, with particular emphasis on the D-iso-
meric tripeptide feG, deserve consideration as poten-
tially therapeutically useful anti-inflammatory agents.
The Neuroendocrine Axis
The existence of salivary-derived, systemically acting,
anti-inflammatory factors and the regulation of salivary
gland function by the sympathetic nervous system were
demonstrated in anaphylaxis and endotoxemia models in
rats. Superior cervical ganglionectomy significantly
reduced mortality and greatly attenuated the influx of
histamine, neutrophils, and serum-derived proteins, into
bronchoalveolar fluid in anaphylaxis-induced pulmonary
inflammation in rats [14]. However, the protective effect
of superior cervical ganglionectomy was completely abol-
ished in rats with concurrent bilateral sialadenectomy of
the submandibular salivary glands [15]. These findings
reveal that submandibular salivary glands produce sys-
temically important immunomodulatory factors and that
the cervical sympathetic nerves tonically inhibit the
release of some of these factors. In an endotoxin-induced
acute hypotension model, either bilateral superior cervi-
cal ganglionectomy or submandibular sialadenectomy
resulted in significantly larger drops in blood pressure
compared to intact controls [16] (Figure 1). These results
indicate that the submandibular gland elaborates factors
that protect against acute hypotension induced by endo-
toxin and that these factors are under the control of the
cervical sympathetic nervous system.
Bioactivity of Salivary Gland Extracts: SGP-T
On the basis of the findings that salivary glands partici-
pate in modulating systemic inflammatory responses,
bioactive factors were sought in saliva. Extracts of sub-
mandibular glands were subjected to molecular weight
cut-off filtration and tested for bioactivity. A novel
seven amino acid peptide with sequence Thr-Asp-Ile-
Phe-Glu-Gly (TDIFEGG) was isolated, named subman-
dibular peptide-T (SGP-T), and shown to express
anti-allergic and anti-endotoxin activities[16,17]. SGP-T
was identified as the carboxyl terminal of SMR1, a 146-
amino acid, multipotent prohormone product of the
VCSa1 (variable coding sequence A1) gene [18], which
is also identified as RATSMR1A, Smr1, SMR1 protein
and VCS-alpha 1. Recent studies have shown that SMR1
is secreted into saliva in response to intraperitoneal
administration of b-adrenergic and cholinergic agonists,
and removal of the cervical sympathetic ganglia that
innervate the salivary glands resulted in increased levels
of SMR1 protein in the submandibular glands [19].
These observations are in keeping with a cervical sym-
pathetic trunk - submandibular gland axis propounded
previously [15].
In ovalbumin (OA) sensitized rats SGP-T at dosages
of 35 and 100 μg/kg injected 10 minutes prior to OA
challenge protected against anaphylactic hypotension
[20]. Interestingly, neither lower nor higher doses (10 or
350 μg/kg) of SGP-T were protective. In OA sensitized
rats challenged intra-intestinally with OA, pretreatment
with SGP-T dose-dependently reduced the incidence
and duration of disrupted intestinal motility and pre-
vented the development of diarrhea [20]. SGP-T treat-
ment also significantly suppressed endotoxin-induced
fever in rats [21]. Neutrophil migration into carrageenan
soaked sponges was inhibited by SGP-T injected intrave-
nously at 100 μg/kg at -1, 0, or 4 hours after implanta-
tion [22]. Interestingly, dose-response assays showed a
bell-shaped dose response curve; neither lower
(10 μg/kg) or higher (350 μg/kg) inhibited neutrophil
migration (Figure 2). SGP-T treatment also promoted a
bell-shaped dose-dependent recovery in the ability of
neutrophils obtained from carrageenan-soaked sponges
to generate superoxide anion. In another study endo-
toxin-induced leukocyte rolling and adhesion, quantified
in vivo by intravital microscopy of mesenteric venules in
Figure 1 Neuroendocrine axis and modulation of responses to
lipopolysaccharide: Intravenous administration of
lipopolysaccharide (LPS) induces rapid reduction in blood pressure
in rats. Either bilateral removal of the submandibular salivary glands
(sialadenectomized) or the superior cervical ganglia
(ganglionectomized) exacerbate the LPS-induced hypotension.
(mean ± sem, n = 6 to 8). Adapted from [16].
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anesthetized rats, was prevented by pre-treatment with
SGP-T [23].
Before considering the pharmacology of SGP-T and its
analogues a brief summary of the VCSa1 gene family
and its products is presented as this subject was recently
reviewed [24].
The VCSa1 Gene Family
The Vcsa1 gene that encodes the rat SMR1 protein is a
member of the variable coding sequence multigene
family, which share a common gene structure but exhi-
bit extensive sequence variation in the coding region of
the genes [25]. The VCS genes, which are divided into
two subgroups VCSA and VCSB, are found exclusively
in mammals [26]. The VCSA family, containing the
Vcsa1 gene, has emerged recently, and exclusively in
rodents, whereas the proline-rich VCSB family is found
in all placental mammals [27]. Human members of the
VCSB family include PROL1, SMR3B (PROL3), and
SMR3A (PROL5) [24], and encode salivary and lacrimal
secreted proline-rich proteins [28-30]. The SMR1 pro-
tein product of the rat Vcsa1 gene is cleaved into at
least two biologically active peptides, sialorphin
(QHNPR) and SGP-T (TDIFEGG) (Figure 3). Whereas
the N-terminal QHNPR sequence is conserved in all
products of the rat VCSA family members, the C-term-
inal TDIFEGG sequence is absent due to mutation or
truncation of the C-terminus [27]. With the absence of
the VCSA subgroup of genes in non-rodent mammals,
sialorphin and SGP-T may not be present, although
homologues of these peptides are encoded by VCSB
genes. The human VCSB gene PROL1 encodes a protein
that contains a QRFSR motif (opiorphin) that is func-
tionally equivalent to rat sialorphin [31], although a
homologue of TDIFEGG (SGP-T) has not been identi-
fied yet. Sialorphin participates in diverse physiological
processes, such as pain perception, antidepressant
effects, sexual behavior, and erectile function [4,32-34],
and these actions appear to be related the inhibition of
neutral endopeptidase (NEP)[4]. Human opiorphin has
similar activity [35]. Vcsa1 expression is hormonally
regulated by androgens [33,36], and the expression of
opiorphin family genes may be similarly regulated [37].
Pharmacology of the Tripeptide D-PHE-D-GLU-
GLY (feG)
During SGP-T isolation and testing procedures, the trun-
cated sequence Phe-Glu-Gly (FEG) was identified, which
itself showed bioactivity, as did its D-isomeric form (feG)
[17]. This tripeptide sequence was synthesized and char-
acterized pharmacologically in various models.
Animal Models
Several rat models of systemic inflammatory disease, and
in vitro or ex vivo immunopharmacologic assays were
utilized to test the bioactivity of feG as follows.
• Endotoxemia models. Injection of lipopolysaccharide
(LPS) in rats results in rapid transient decreases in
blood pressure, increases in circulating leukocytes,
migration of leukocytes into peritoneal fluid, accumula-
tion of neutrophils in cardiac tissue, disrupted intrinsic
rhythmicity of migrating myoelectric complexes (MMC)
in intestines, etc.
• Anaphylaxis. Rats sensitized to ovalbumin (OA) or
larvae of Nippostrongylis braziliensis (Nb) and
Figure 2 SGP-T and neutrophil chemotaxis: Neutrophil
chemotaxis into carrageenan-soaked sponges over a 24 hour period
in rats is inhibited by SGP-T injected intravenously, in a bell-shaped
dose-dependent manner, at dosages indicated. (mean ± sem, n = 3
to 12). Adapted from [22].
Figure 3 eptide Products from Submandibular Rat-1 (SMR1)
Prohormone: The SMR1 precursor protein contains sialorphin near
the N-terminal, and SGP-T (submandibular gland peptide T) near the
C-terminal. FEG and FEG(NH2) are biologically active derivatives of
SGP-T.
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subsequently challenged with these same antigens by
injection, orally, or intra-nasally depending on the pur-
poses of the experiment, develop rapid drops in blood
pressure; accumulation of leukocytes in cardiac tissue;
increases in vascular permeability; increased circulating
leukocytes; diarrhea and disrupted MMCs; and IgE-
mediated migration of eosinophils, neutrophils, and
monocytes into airways.
• Pulmonary bronchoconstriction (measured by speci-
fic lung resistance) and airway hyper-responsiveness to
methacholine or carbachol in sheep naturally allergic to
Ascaris suum or in rats sensitized with either OA or
with larvae of Nb and challenged by aerosol administra-
tion of the sensitizing antigens was measured after aero-
sol challenge with the antigen.
• Spinal cord injury in rats induced by 60 second clip
compression of the spinal cord was measured by lesion
site histology and histochemistry as well as recovery of
locomotor function.
• Pancreatitis induced in mice by intravenous injection
of caerulein was measured histologically, by determina-
tion of plasma amylase and lipase activity, and by
immunoassays.
• In vitro and ex vivo studies on leukocyte migration,
adhesion, cell surface marker expression, and reactive
oxygen species production.
Hypotension
An early observation was that treatment with feG, like
its predecessor SGP-T, inhibited the decrease in blood
pressure associated with anaphylactic shock [38]. Chal-
lenge of sensitized rats with OA administered orally
evoked a rapid drop in ventricular peak systolic pressure
(VPSP) of 50 to 70 mm Hg. In normal rats or in unchal-
lenged OA sensitized rats intravenous administration of
SGP-T, FEG, or feG had no effect on resting VPSP at
any dosage. However, in OA challenged rats, intrave-
nous administration of each of the peptides 10 minutes
prior to challenge significantly protected against the
drop in VPSP compared to saline treated controls.
Importantly, oral administration of feG 20 minutes
before OA challenge also produced a dose-dependent
inhibition of cardiovascular shock (Figure 4).
Leukocyte migration
Neutrophil migration into carrageenan-soaked sponges
24 hours after subcutaneous implantation in rats was
inhibited by intraperitoneal injection of feG at
100 μg/kg [39] (Figure 5). Neutrophil inflitration was
significantly reduced by feG treatment in an acute pan-
creatitis model in mice [40] and also in a spinal cord
injury model in rats [41].
Oral challenge in OA sensitized rats induces systemic
effects including increased circulating leukocytes, leuko-
cyte infiltration into the heart, increased vascular perme-
ability, and pulmonary inflammation [42]. Changes in
vascular permeability occurred within 30 minutes, periph-
eral blood neutrophilia appeared by 3 hours, and signifi-
cant accumulation of neutrophils in the heart, detected by
a 75% increase in myeloperoxidase (MPO) content, was
seen at 24 hours after oral OA challenge. Treatment with
feG intraperitoneally 20 minutes before antigen challenge
significantly inhibited the increase in vascular permeabil-
ity, circulating leukocytes and neutrophils, and neutrophil
Figure 4 feG and cardiovascular anaphylaxis: Anaphylaxis
induced by ovalbumin (OA) challenge in previously sensitized rats
causes rapid reduction in blood pressure (control). feG treatment
orally at the time of OA challenge dose-dependently inhibited
anaphylaxis-induced hypotension. (mean ± sem, n = 5 to 6).
Adapted from [38].
Figure 5 feG and neutrophil migration: Neutrophils migrate into
carrageenan-soaked surgical sponges implanted subcutaneously in
rats. feG, at a dosage of 100 μg/kg injected intraperitoneally at the
time of sponge implantation, significantly inhibited neutrophil
migration measured 24 hours after implantation. (mean ± sem,
n = 6 to 10). Adapted from [39].
Mathison et al. Journal of Inflammation 2010, 7:49
http://www.journal-inflammation.com/content/7/1/49
Page 4 of 11
infiltration into the heart. Intraperitoneal injection of feG
at 100 μg/kg at the time of oral OA challenge of sensitized
rats almost completely inhibited the increase in circulating
neutrophils detected 18 hours after challenge [43]. Pul-
monary airway inflammation in OA sensitized rats was
also inhibited by feG. Oral treatment with feG 30 minutes
to 6 hours after oral OA challenge significantly inhibited
neutrophil and eosinophil numbers in airways 24 hours
after challenge [44] (Figure 6). In another study, oral treat-
ment with feG at dosages of 250 and 1,000 μg/kg 30 min-
utes before OA challenge inhibited influx of neutrophils,
monocytes, and eosinophils into bronchoalveolar lavage
fluid (BAL) but had no effect on lymphocytes [45].
Infusion of LPS in rats also causes accumulation of
neutrophils in heart tissue in addition to acute hypoten-
sion [46]. Intravenous treatment with a carboxamide
derivative, feG(NH2), at the time of LPS infusion, dose-
dependently inhibited accumulation of neutrophils in
atrial slices 24 hours after intravenous LPS (Figure 7).
Orally administered feG (100 μg/kg) also significantly
reduced the number of macrophages and neutrophils
recovered in peritoneal lavage fluid 24 hours after LPS
challenge [47].
Intestinal effects
Oral challenge with OA in sensitized rats also results in
disrupted intrinsic rhythmicity MMCs in the small
intestine, and in diarrhea in 85% of challenged animals
[38,48]. Oral dosage of feG at 350 μg/kg at the time of
OA challenge totally abolished the intestinal anaphylac-
tic reaction and diarrhea in all rats tested. In a similar
study feG given orally 30 minutes before OA challenge
dose dependently inhibited anaphylaxis-induced intest-
inal motility, with maximal inhibition achieved at the
highest dosage-100 μg/kg [49]. Interestingly, feG dosage
(100 μg/kg) up to 8 hours before challenge afforded sig-
nificant protection against intestinal anaphylaxis, sug-
gesting a long biological half life (Figure 8) [49].
Infusion of LPS in rats also has acute effects on the
intestine by disrupting the standard MMCs and pro-
duces a pattern of intense, irregular myoelectricity [50]
Figure 6 Allergen induced by aerosol challenge with
ovalbumin (OA) in previously sensitized rats causes pulmonary
airway inflammation: feG treatment orally 30 minutes, 3 hours, or
6 hours after OA challenge inhibited the influx of eosinophils and
neutrophils into airways. Adapted from [44].
Figure 7 Neutrophil accumulation in heart tissue: Intravenous
administration of lipopolysaccharide (LPS) in rats causes
accumulation of neutrophils in heart tissue as detected by
myeloperoxidase (MPO) activity in atrial slices 24 hours after LPS
infusion. Intravenous treatment with a carboxamide derivative, feG
(NH2), at the time of LPS infusion, dose-dependently inhibited MPO
in atrial slices. (mean ± sem, n = 4 to 8). Adapted from [46].
Figure 8 feG and intestinal allergic responses: Oral challenge
with ovalbumin (OA) in sensitized rats results in disrupted intrinsic
rhythmicity of migrating myoelectric complexes (MMC) in the small
intestine. feG injected intravenously at 100 μg/kg up to 8 hours
before challenge significantly reduced disruption in MMCs,
suggesting a long biological half life (mean ± sem, n = 4 to 8).
Adapted from [49].
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Intravenous injection of feG 20 minutes before LPS
dose-dependently reduced the length of time of disrup-
tion of jejunal MMCs. Interestingly, the carboxamide
derivative, feG(NH2), was found to be more potent than
feG in this endotoxemia model. feG given orally 20 min-
utes before LPS challenge inhibited disruption of MMCs
in a bell shaped, dose-dependent manner, with 65 μg/kg
providing maximal inhibition.
Effects on pulmonary inflammation and function
Effects of feG treatment were further studied in pul-
monary inflammation models in rats sensitized with
either OA or with larvae of Nippostrongylis braziliensis
(Nb) and challenged by aerosol administration of the
sensitizing antigens [45], Oral treatment with feG at 1
mg/kg 30 minutes prior to OA challenge significantly
reduced airway hyper-responsiveness to methacholine
measured 24 hours after challenge. In Nb sensitized rats
feG significantly reduced tracheal smooth muscle con-
traction in response to aerosol Nb challenge.
In asthmatic sheep naturally sensitized to Ascaris
suum, bronchoconstriction, determined by measuring
specific lung resistance (SRL), and airway hyper-
responsiveness to carbachol were measured in instru-
mented sheep after aerosol challenge with the antigen
[51]. Bronchoconstriction (SRL) increased rapidly up to
500% immediately after aerosol challenge, decreased to
baseline values over 3 hours, but was followed by a sec-
ondary increase in SRL 5 hours after challenge. Treat-
ment with feG intravenously (1 mg/kg) or orally (2 mg/
kg) had no effect on the early, acute phase increase in
SRL, but inhibited the late phase increase by 72% and
78% respectively relative to challenged untreated con-
trols (Figure 9). Inhaled feG, at a dose of 30 mg/sheep,
reduced early (by 83%) as well late (by 88%) broncho-
constriction. Airway hyper-responsiveness to carbachol,
measured 24 hours after antigen challenge, was signifi-
cantly inhibited by pre-challenge treatment with feG
intravenously, orally, or by aerosol delivery.
In cats sensitized to Bermuda grass allergen, adminis-
tration of feG orally at 1 mg/kg immediately prior to
allergen challenge resulted in a significant reduction in
accumulation of eosinophils in bronchoalveolar lavage
fluid [52]. However, daily treatment for 2 weeks in
experimentally asthmatic cats had no measurable effect
on airway inflammation [53]. This latter result suggests
that further studies will be necessary to evaluate dosing
regimens and formulation for feG (see Pharmacody-
namic/pharmacokinetic considerations below).
Vascular Permeability
The effects of feG on vascular permeability induced by
antigen challenge and histamine have been studied in
both rats and dogs. With both species intradermal injec-
tion of feG (10-6M to 10-9M) significantly reduced the
increase in vascular leak of a dye (Evans blue) provoked
by both active cutaneous anaphylaxis and histamine by
up to 40% at high doses to ~20% at lower doses (unpub-
lished observations).
Other disease models: acute pancreatitis, spinal cord
injury
In acute pancreatitis, induced in mice by 12 hourly
injections of caerulein, a single dose of feG (100 μg/kg)
was administered intraperitoneally at induction (prophy-
lactic) or 3 hours post induction (therapeutic) [40].
Plasma lipase activity was reduced in feG groups treated
both prophylactically and therapeutically; amylase was
reduced in feG groups treated prophylactically (Figure
10). Histologically, feG treatment reduced pancreatitis-
induced edema and acinar cell necrosis.
In a clip compression model of spinal cord injury in
rats, leukocyte infiltration, free radical formation, and
oxidative damage at the lesion site were quantified [41].
Neutrophil infiltration, detected by MPO activity, and
activated phagocytic macrophages, identified by ED-1
expression, were present within 24 hours of injury.
Intravenous feG treatment 2, 6, or 12 hours after injury
reduced MPO activity, ED-1 expression, oxidative
enzymes, free radical production, lipid peroxidation, and
cell death (caspase-3 expression) in injured cord lesion
sites. These anti-inflammatory and anti-oxidative actions
of feG treatment correlated with improved neurological
outcomes after spinal cord injury. In a similar spinal
Figure 9 feG and asthma in sheep: In asthmatic sheep naturally
sensitized to Ascaris suum, bronchoconstriction determined by
measuring specific lung resistance (SRL) increased rapidly
immediately after aerosol challenge, decreased to baseline values
over 4 hours, but was followed by a secondary increase in SRL 5
after hours post challenge. Inhaled feG at a dose of 30 mg/sheep
reduced early as well as late increases in SRL, whereas treatment
with feG intravenously (1 mg/kg) or orally (2 mg/kg) inhibited only
late phase bronchoconstriction. (mean ± sem, n = 4 to 8). Adapted
from [51].
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cord injury model feG given intravenously at 200 μg/kg
twice daily for 5 days improved locomotor and allodynia
scores relative to controls over 7 weeks following cord
injury [54] (Figure 11).
Pharmacodynamic/pharmacokinetic considerations
From a pharmacodynamic perspective, it appears that
feG has a long biological half life. Single intravenous
dosages of feG inhibit endotoxin-provoked accumulation
of neutrophils in cardiac tissue for at least 24 hours [46]
(see Figure 7). Single oral dosage of feG in OA sensi-
tized challenged rats also inhibits neutrophil and
eosinophil migration into airways for at least 24 hours
[44] (see Figure 6). Likewise in asthmatic sheep intrave-
nous, oral, or aerosol administration of feG blocks air-
way responsiveness for at least 24 hours after antigen
challenge [51].
Bell shaped dose-response relationships were observed
in various assays, so frequently as to not be dismissible
as coincidental. First observed with SGP-T inhibition of
anaphylaxis-induced hypotension in rats [55] and inhibi-
tion of neutrophil migration into carrageenan soaked
sponges [22] (see Figure 5), feG treatment also resulted
in a biphasic dose-response curve in an intestinal endo-
toxemia model [38]. In vitro incubation of human neu-
trophils with feG within a window of molar
concentrations between 10-11 to 10-9 M down regulated
platelet activating factor- (PAF) induced expression of
CD 11b (AlphaM integrin chain) and PAF-induced neu-
trophil migration [39] (Figure 12). Within these same
molar concentrations feG inhibited fibrinogen and fibro-
nectin binding of peritoneal leukocytes from rats that
had been infused with LPS 18 hours earlier. Binding of
leukocytes from LPS treated rats to atrial slices was
inhibited by feG in vitro at concentrations of 10-9M but
not 10-7M [46]. These findings suggest that dosage of
feG may be critical to achieve the desired therapeutic
effect.
Pharmacokinetic studies, to our knowledge, have not
been performed on feG in any species. However, results
of preliminary pharmacokinetic and toxicokinetic studies
have been performed on a closely-related salivary tripep-
tide (D-cyclohexylalanine-D-glutamate-glycine; (cha)eG)
in rats, dogs, and monkeys (proprietary, in-house data,
2010). In rats and dogs oral dosages of 2,500 μg/kg of
Figure 10 feG and acute pancreatitis. In acute pancreatitis,
induced in mice by 12 hourly injections of caerulein, a single
intraperitoneal dose of feG (100 μg/kg) administered at start of
caerulein induction or 3 hours after start of induction, inhibited
plasma lipase and amylase activity. Adapted from [40].
Figure 11 feG and spinal cord injury: In a spinal cord injury
model induced by 60 second clip compression of the spinal cord,
rats given feG intravenously at 200 μg/kg twice daily for 5 days had
higher BBB locomotor scores compared to controls (p = 0.043) over
7 weeks following cord injury. Adapted from [54].
Figure 12 feG and human neutrophils: Incubation of human
neutrophils with feG within a window of molar concentrations
between 10-11 to 10-9 M downregulated platelet activating factor-
(PAF) induced neutrophil migration in vitro. (mean ± sem, n = 3
to 7). Adapted from [39].
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(cha)eG were required to achieve detectable plasma con-
centrations (>5 ng/mL). Oral bioavailability was esti-
mated to be less than 1% in the rat. In monkeys
detectable plasma levels of (cha)eG persisted for 24
hours following a single intravenous dosage of 10 mg/
kg, with an apparent terminal half life of approximately
9 hours, consistent with pharmacodynamic findings in
rats (see Figure 8). However, noting that in vitro feG is
active within a window of concentrations of about
0.0035 to 0.35 ng/mL, and that in model studies in rats
feG dosage of 100 μg/kg was consistently found to be
effective regardless of route of administration, it must
be concluded that the systemic bioactivity of feG occurs
at concentrations well below minimum detectable
plasma concentrations of current assays. In other words,
the dosage riddle is unlikely to be solved by
pharmacokinetics.
Mechanism studies: Effect of feG on neutrophil
chemotaxis, adhesion, and function
Results of in vivo studies point to the neutrophil as the
primary target cell for the immunopharmacologic
actions of feG and other bioactive factors produced by
the salivary gland. Early results showed that SGP-T
treatment inhibited neutrophil chemotaxis [22] as well
as rolling [23].
Effect on adhesion
In peritoneal neutrophils collected from OA sensitized
rats 24 hours after challenge, pre-treatment with feG
had no effect on expression of the alpha integrin CD
11b but down regulated expression of the beta 1 integ-
rin CD49 d (Alpha-4 integrin chain) [42]. In vitro incu-
bation of human neutrophils with feG inhibited PAF
induced neutrophil migration (see Figure 12) as well as
expression of CD 11b [39]. In normal (unstimulated)
neutrophils feG had no effect on neutrophil adhesion to
gelatin, whereas in PAF-activated cells feG at 10-11 and
10-10M significantly inhibited adhesion of human neu-
trophils. However, within molar concentrations of 10-11
to 10-9 M, feG had no effect on PAF-stimulated super-
oxide release or on phagocytotic activity, suggesting that
feG modulates primarily neutrophil adhesion and migra-
tory responses. Peritoneal neutrophils from OA sensi-
tized rats 24 hours after challenge were also tested for
expression of CD11b and CD16b (Fc-gamma RIIIb: Low
affinity immunoglobulin gamma Fc region receptor
IIIB). feG treatment (100 μg/kg orally) inhibited CD 11b
antibody binding to peritoneal neutrophils in unchal-
lenged but not in OA challenged rats. CD 16b binding,
however, was inhibited by feG treatment in both chal-
lenged and unchallenged rats. In vitro (microtiter plates)
feG inhibits adhesion of rat peritoneal leukocytes, but
only if the cells were stimulated with PAF[43], indicating
that feG’s actions require cell activation. feG treatment
also completely blocked the expression of the beta
1-integrin CD49 d on circulating neutrophils which was
up regulated by OA challenge, but had no effect on
CD11b expression. These and other findings led to the
conclusion, that when administered in vivo feG prevents
inflammation-induced reduction in cell adhesion as well
as restoring its inhibitory effect in vitro.
Effect on oxidative activity
Neutrophils, which play a key role in the development
and perpetuation SIRS, inactivate and destroy virulent
pathogens through the release of superoxide and
enzymes and by phagocytosis [56]. In OA sensitized rats
the extracellular release of superoxide anion by circulat-
ing neutrophils 18 hours after OA challenge was not
modified by either OA challenge or feG treatment [57],
confirming similar findings in previous studies [39].
However, incubation of the cells with phorbol myristate
acetate (PMA), a protein kinase C (PKC) activator,
increased intracellular release of reactive oxygen species
as determined by flow cytometry for a marker of oxygen
free radicals, 123-dihydrorhodamine. feG treatment at
the time of challenge inhibited intracellular superoxide
production by PMA-stimulated blood neutrophils 18
hours after challenge (Figure 13). These findings led to
the speculation that feG reduces the capacity of neutro-
phils to generate reactive oxygen species by preventing
the deregulation of PKC consequent to an allergic
reaction.
Saliva, in addition to its role as a digestive aid, contri-
butes significantly to lubrication, protection, defence and
Figure 13 feG and the oxidative burst: - Dose-response for
phorbol myristate acetate- (PMA) stimulated intracellular oxidative
activity of circulating neutrophils 18 hours after ovalbumin (OA)
challenge in OA sensitized rats. feG was injected intraperitoneally at
100 μg/kg at the time of challenge. Oxidative activity was measured
using flow cytometry for a marker of oxygen free radicals, 123-
dihydrorhodamine. (mean ± sem, n = 6 to 7). Adapted from [57].
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wound healing in the mouth. The importance of salivary
glands and their secretions are poorly appreciated, and
they are only taken seriously when salivary gland dys-
function results in decreased saliva flow. In humans this
dysfunction contributes to difficulties in tasting, eating,
swallowing, and speaking, and results in sores of the soft
tissues of the mouth and periodontal disease. These
pathologies also manifest in human patients with a vari-
ety of systemic diseases including - Sjögren’s syndrome,
rheumatoid arthritis, juvenile idiopathic (rheumatoid)
arthritis, systemic lupus erythematosus (an inflammatory
connective tissue disease), systemic sclerosis (scelo-
derma), primary bilary cirrhosis (an autoimmune disease
of the liver), sarcidosis (a multisystem granulomatous dis-
order), infections with human immunodeficiency virus,
herpes virus, hepatitis C, ectodermal dysplasia, chronic
pancreatitis and depression [58].
Nonetheless, it should be recognized that the relation-
ship between salivary glands and systemic health is
bidirectional. “Oral infection may represent a significant
risk-factor for systemic diseases, and hence the control
of oral disease is essential in the prevention and man-
agement of these systemic conditions” [59]. Chronic
inflammatory periodontal diseases are among the most
prevalent chronic infections in humans, and many inves-
tigators have established a significant, albeit modest,
positive association between periodontal disease and
cardiovascular disease, which includes atherosclerosis,
myocardial infarction and stroke. In addition, epidemio-
logical associations have been made between periodontal
diseases and chronic diseases such as diabetes, respira-
tory diseases and osteoporosis [60].
Likewise in veterinary medicine epidemiologic studies
reveal that oral disease is the most common disease in
all age groups of dogs and cats [61]. Moreover, there is
evidence that oral infection also has systemic effects
including renal, hepatic, pulmonary, and cardiac dis-
eases; osteoporosis, adverse pregnancy effects, and dia-
betes mellitus [62], and can lead to systemic
inflammation [63]. The severity of periodontal disease
was found to be positively correlated with histological
changes in kidneys, myocardium, and liver [64].
In this review we focused on SGP-T and its derivatives
namely FEG and its D-isomeric derivative feG, which in
themselves demonstrate the significant physiological and
immunological modulation exerted by salivary gland
peptides. These peptides have significant anti-inflamma-
tory actions, as shown in animal models of endotoxic
shock (Figures 1 &7), allergic and anaphylactic reactions
(Figures 4, 6, 8 &9), pancreatic (Figure 10) and spinal
cord injury (Figure 11).
feG, and its analogues, exhibit a distinctly differ-
ent mechanism of anti-inflammatory action from
corticosteroids and nonsteroidal anti-inflammatory
drugs (NSAIDs). NSAIDs and corticosteroids have
become the mainstay of anti-inflammatory agents in
human and veterinary medicine. NSAIDs are popular
owing to their immune sparing effect, especially since
the discovery that they act by inhibiting cyclooxygen-
ase (COX), an enzyme that catalyses the arachidonic
acid cascade resulting in production of pro-inflamma-
tory eicosanoids [65]. In contrast to enzymatic block-
ade, the tripeptide feG has multimodal activity and
acts directly on activated leukocytes, specifically down
regulating expression of integrins, thereby inhibiting
chemotaxis (Figures 2 &12) and cell migration (Figure
5). Furthermore, feG inhibits the function of neutro-
phils by specifically inhibiting intracellular superoxide
production by activated neutrophils (Figure 13), prob-
ably as a consequence of interruption of the signaling
cascade that induces superoxide generation [66].
Hence feG and its analogues appear to represent a
new class of anti-inflammatory agents which act on
immune cells, the central regulators of all inflammation.
The term “Immune Selective Anti-Inflammatory Deriva-
tives” (ImSAIDs) is proposed for salivary-derived pep-
tides to distinguish this class of agents from
corticosteroids and NSAIDs. A closely-related salivary
tripeptide ((cha)eG) is currently under investigation as
an anti-asthmatic therapeutic in humans.
Conclusions
Based on its mechanism of action and demonstrable in
vivo pharmacologic activity, feG deserves evaluation in a
number of situations characterized by over-exuberant or
chronic inflammatory responses of human and veterin-
ary significance associated with several major organ sys-
tems:
• Whole body and circulatory: sepsis, endotoxemia,
SIRS [67];
• Gastrointestinal: pancreatitis, hepatitis, gastroenter-
itis, enteritis;
• Oral cavity: stomatitis
• Respiratory: asthma, acute pulmonary inflamma-
tion of diverse etiologies;
• Musculo-Skeletal: fibromyalgia, rheumatoid arthri-
tis, equine laminitis (now characterized as a neutro-
phil-mediated inflammatory disease [68]);
• Nervous: spinal cord injury, peripheral nerve
injury;
• Urinary tract: cystitis
Aside from these therapeutic potentials, feG may
eventually prove to be useful as a vetraceutical or a
nutraceutical [the term coined by Stephen DeFelice
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[69]] to reduce the incidence and severity of systemic
and localized inflammations caused by intense exercise,
poor oral health and other causes.
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